Search the Newsreel

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis …

EXELIXIS, INC. SEC Filing (Aug 10, 2026)

This article reports on an SEC Form 144 filing by Exelixis, Inc. (EXEL) on August 10, 2026. The filing indicates a proposed sale of 9,812 shares of common stock with an aggregate market value of $526,496.22, acquired on May 29, 2026, through a restricted …

(EXEL) as a Liquidity Pulse for Institutional Tactics

This article analyzes Exelixis Inc. (NASDAQ: EXEL) using AI models to provide institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with a significant 26.9:1 risk-reward setup. Three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—are detailed, alongside multi-timeframe signal …

Helix Resources Limited (HLXDB.AX) stock price, news, quote and history

Investor Alert: Deadline Approaching to Join Telix Pharmaceuticals Ltd. (TLX) Class Action - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has announced a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding …

Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $20.40. The stock recently traded up 8.3% at $11.52, remaining above its 50-day and 200-day moving averages. Institutional investors have also increased their positions …

Did Stronger Q2 Earnings and Lowered 2026 Guidance Just Recast Exelixis' (EXEL) Oncology Narrative?

EXELIXIS ($EXEL) announced its Q2 2026 earnings, reporting $0.91 per share, which surpassed estimates. However, the company's revenue of $628.69 million fell short of expectations. Following the announcement, the stock experienced a 5.23% decline.

Helix Energy Solutions Group (HLX) Stock Faces Margin Doubts After Profit Return

Helix Energy Solutions Group (HLX) returned to profit in Q2 2026 with basic EPS of US$0.10, but its stock slipped due to concerns over a modest 2.6% trailing net margin and a high P/E of 41x. While the company is shifting towards higher-margin offshore …

Helix Energy Solutions Group (NYSE:HLX) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Helix Energy Solutions Group (NYSE:HLX) reported quarterly earnings of $0.10 per share, surpassing analyst expectations by $0.02, although revenue of $304.02 million fell short of estimates. The company's stock traded down $0.19 to $9.62, with institutional investors holding a significant portion of the shares. …

Helix Energy Solutions Group (NYSE:HLX) Rating Increased to Buy at Wall Street Zen

Wall Street Zen has upgraded Helix Energy Solutions Group (NYSE:HLX) from a "Hold" to a "Buy" rating, though other analysts remain divided with an average "Hold" rating and a $14.00 consensus price target. The company reported quarterly earnings that beat estimates but revenue that …

Delixy Holdings Ltd (DLXY) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Delixy Holdings Ltd (DLXY), detailing future estimates for EPS and revenue growth. It includes an overview of the company's current stock performance, market capitalization, and a comparison with peer companies in the Oil & Gas sector. The …

Delixy Holdings Ltd (DLXY) Stock News Today

This article provides current stock information for Delixy Holdings Ltd (DLXY), noting its present trading price, market cap, and a statement that more news is coming soon. It appears to be a placeholder page for news related to the company, indicating a lack of …

Helix Resources Limited (HLXDB.AX) interactive stock chart

HELIX ENERGY SOLUTIONS GROUP INC 2026: Revenue $304.02M, EPS $0.15— 10-Q Summary

Helix Energy Solutions Group Inc. reported strong financial results for the 2026 quarter, with consolidated revenue increasing by 20.8% to $304.02 million and diluted EPS rising significantly to $0.15 from a loss in the prior year. The growth was primarily driven by its Well …

Exelixis, Inc. Stock 12‑Month Price Target Raised to $52.62, Implies 7% Downside

Exelixis, Inc.'s average stock price target has been raised from $52.25 to $52.62 by 16 analysts, suggesting a potential 7% downside based on the August 5 closing price. Despite the raised target implying a decrease, the consensus rating for EXEL remains a "Buy" from …

EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q4 FY2025 earnings call transcript

Exelixis reported Q4 2025 revenues of $599M, primarily driven by a 6% year-over-year increase in U.S. CABOMETYX sales to $547M, with full-year 2025 U.S. CABOMETYX revenue reaching $2.12B, up 17% year-over-year. The company is preparing for a potential late 2026 launch of zanzalintinib for …

Quantinno Capital Management LP Boosts Holdings in Exelixis, Inc. $EXEL

Quantinno Capital Management LP significantly increased its stake in Exelixis, Inc. by 44.3% in the first quarter, now holding 115,592 shares valued at approximately $4.96 million. This increase occurred despite mixed analyst ratings and recent insider selling. Exelixis reported strong second-quarter adjusted earnings but …

Helix Energy Posts Profit, Anticipates Hornbeck Merger Completion

Helix Energy (HLX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, July 29, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Executive Vice President and Chief Financial Officer - Erik StaffeldtChairman of the Board - Bill TransierExecutive Vice President and Chief Operating Officer - Scott SparksChairman, President, and Chief …

EXELIXIS INC : LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM

Leerink Partners has downgraded its rating for Exelixis Inc (EXEL.O) from "Outperform" to "Market Perform." This change indicates a revised outlook on the pharmaceutical company's stock performance. The update was reported by Reuters.

Elixinol Wellness Reports Record Q2 FY26 Revenue of $4.3m with 45% Gross Margin at Coffee Microcaps Presentation

Elixinol Wellness Builds Margin-Strong Platform for Growth

EDGAR Filing Documents for 0000866829-26-000021

This SEC filing details a Form 8-K for HELIX ENERGY SOLUTIONS GROUP INC (CIK: 0000866829), submitted on August 6, 2026. The report includes items related to results of operations, financial condition, and regulation FD disclosure, accompanied by numerous exhibits and interactive data files. The …

Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot

Exelixis (EXEL) saw its stock drop 6.7% after cutting its 2026 revenue outlook to $2.50 billion–$2.55 billion. This revision came despite solid Q2 earnings and is attributed to slower growth in the neuroendocrine tumor indication and continued heavy investment in its zanzalintinib pipeline and …

Helix Energy Solutions Group Jumps 6.0% on EPS Beat

Helix Energy Solutions Group (HLX) saw its shares surge by 6.0% to $9.88 after reporting strong second-quarter 2026 earnings. The offshore energy services provider posted earnings per share of $0.50 on revenue of $304.0 million, exceeding expectations and boosting its market capitalization to $1.5 …

EXELIXIS, INC. Q2 2026: Revenue $628.69M, EPS $0.82— 10-Q Summary

EXELIXIS, INC. reported strong second-quarter 2026 results with revenue of $628.69M and diluted EPS of $0.82, showing significant year-over-year growth due to increased product demand and price gains. Key drivers included CABOMETYX sales, progress in pipeline development with zanzalintinib, and expanded clinical trials. The …

Exelixis Inc (EXEL) Beats EPS Estimate with $0.82 and Reports Revenue of $628.7 Million -- Is the Stock Overvalued?

Exelixis Inc (EXEL) reported strong financial results for Q2 2026, surpassing analyst expectations with total revenues of $628.7 million and a GAAP diluted EPS of $0.82. The biopharmaceutical company, known for its cancer treatments like cabozantinib, updated its fiscal year 2026 guidance, projecting total …

Earnings Flash (HLX) Helix Energy Solutions Group, Inc. Reports Q2 Revenue $304.0M

Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EXEL) 2026-08-06

Exelixis, Inc. published its Q2 2026 earnings call presentation. The company reported EPS of $0.91, beating estimates by $0.02, but revenue of $628.69M missed expectations by $7.46M, despite a 10.63% year-over-year increase. The slide deck provides detailed information discussed during the earnings call.

EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View

Exelixis, Inc. (EXEL) reported mixed results for Q2 2026, beating earnings estimates with 82 cents EPS but missing revenue forecasts at $628.7 million. The company lowered its full-year 2026 revenue guidance due to a slower-than-expected ramp-up of its neuroendocrine tumor indication for Cabometyx. Despite …

Pacer Advisors Inc. Buys New Shares in Helix Energy Solutions Group, Inc. $HLX

Pacer Advisors Inc. acquired 535,710 shares of Helix Energy Solutions Group, valued at approximately $5.3 million, during the first quarter, representing 0.36% of the company. Institutional investors collectively own 91.33% of Helix's outstanding shares, with several firms like Millennium Management and Invesco recently increasing …

Helix Energy Solutions Group (HLX) Earnings Date and Reports 2026 $HLX

Zacks Research Predicts Exelixis' Q3 Earnings (NASDAQ:EXEL)

Helix Energy (NYSE: HLX) boosts profit, sells Helix Alliance and plans Hornbeck merger

Helix Energy (HLX) Q2 Earnings and Revenues Beat Estimates

Exelixis (EXEL) Stock Drops As Guidance Cut Clouds Profit Strength